CIK 0001001233
- Non-accelerated filer
- Smaller reporting company
SANGAMO THERAPEUTICS, INC
Sign in to watch- Ticker
- SGMOQ
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680359556
- Phone
- +1 510-970-6000
- Business address
- 501 CANAL BLVD., RICHMOND, CA, 94084
- Former names
- SANGAMO BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-23 | LOEB GARY EVP, General Counsel & Sec. | Exercise or conversion | +11,981 | $11.02 | $132K | 100,762 |
| 2021-03-23 | LOEB GARY EVP, General Counsel & Sec. | Sale | −11,981 | $13.10 | $157K | 88,781 |
| 2021-03-23 | LOEB GARY EVP, General Counsel & Sec. | Sale | −5,000 | $13.18 | $66K | 83,781 |
| 2021-03-23 | LOEB GARY EVP, General Counsel & Sec. | Sale | −543 | $13.17 | $7K | 83,238 |
| 2021-03-23 | LOEB GARY EVP, General Counsel & Sec. | Exercise or conversion · Stock Option (Right-to-Buy) | −11,981 | 238,019 | ||
| 2021-02-25 | Duraibabu Prathyusha VP, PFO and PAO | Shares withheld for taxes | −1,863 | $11.19 | $21K | 27,385 |
| 2021-02-25 | Duraibabu Prathyusha VP, PFO and PAO | Grant or award | +13,750 | 41,135 | ||
| 2021-02-25 | Duraibabu Prathyusha VP, PFO and PAO | Grant or award · Stock Option (Right to Buy) | +27,500 | 27,500 | ||
| 2021-02-25 | Duraibabu Prathyusha VP Principal Acct. Officer | Shares withheld for taxes | −1,863 | $11.19 | $21K | 27,385 |
| 2021-02-25 | Duraibabu Prathyusha VP Principal Acct. Officer | Grant or award | +13,750 | 41,135 | ||
| 2021-02-25 | Duraibabu Prathyusha VP Principal Acct. Officer | Grant or award · Stock Option (Right to Buy) | +27,500 | 27,500 | ||
| 2021-02-25 | Ramelmeier Rolf Andrew EVP, Technical Operations | Shares withheld for taxes | −7,779 | $11.19 | $87K | 58,199 |
| 2021-02-25 | Ramelmeier Rolf Andrew EVP, Technical Operations | Grant or award | +40,000 | 98,199 | ||
| 2021-02-25 | Ramelmeier Rolf Andrew EVP, Technical Operations | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2021-02-25 | McClung David Mark EVP, Chief Business Officer | Grant or award | +40,000 | 140,000 | ||
| 2021-02-25 | McClung David Mark EVP, Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2021-02-25 | LOEB GARY EVP, General Counsel & Sec. | Shares withheld for taxes | −5,762 | $11.19 | $64K | 44,781 |
| 2021-02-25 | LOEB GARY EVP, General Counsel & Sec. | Grant or award | +44,000 | 88,781 | ||
| 2021-02-25 | LOEB GARY EVP, General Counsel & Sec. | Grant or award · Stock Option (Right to Buy) | +88,000 | 88,000 | ||
| 2021-02-25 | Macrae Sandy President and CEO | Shares withheld for taxes | −35,311 | $11.19 | $395K | 208,691 |
Page 16 of 17 · 338 trades